Oct 1, 2007
By:
Laura Bush
Today, product costs, not process science, cause the most concern.
|
Sep 1, 2007
By:
Laura Bush
In analyzing the industry's current challenges, let's be careful before extrapolating about what they mean.
|
Aug 1, 2007
By:
Laura Bush
The corruption of China's food and drug sectors is not limited to one man. Likewise, real reform will require the efforts of many.
|
Jul 1, 2007
By:
Laura Bush
Quality guidelines are only as good as their implementation.
|
Jun 1, 2007
By:
Laura Bush
Without charges for some large merger deals, the publicly traded US biopharmaceutical industry would have been profitable in 2006—for the first time.
|
May 1, 2007
By:
Laura Bush
Fortunately for all of us, not everyone's head is in the sand.
|
Apr 1, 2007
By:
Laura Bush
Financial pressure to show short-term results also affects the pharmaceutical industry, from Big Pharma to small biotech.
|
Mar 22, 2007
By:
Laura Bush
The United States Pharmacopeia (USP, Rockville, MD, www.usp.org) and the UK's National Institute for Biological Standards and Control (NIBSC, Hertfordshire, UK, www.nibsc.ac.uk) are seeking participants in a study of analytical methods used by the industry to characterize and quantify oligosaccharides.
|
Mar 22, 2007
By:
Laura Bush
The biopharmaceutical industry has gained a lot of experience in monitoring glycosylation, but still has a lot to learn about the structure–function relationship.
|
|
